Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Lifordi Immunotherapeutics General Information
Lifordi's lead candidate LFD-200 has demonstrated efficacy in multiple preclinical disease models, including a rheumatoid arthritis mouse model. In non-human primates, LFD-200 showed a relatively low serum half-life of 14 hours, but its payload is retained in immune organs for longer periods, supporting reduced systemic toxicity and lower dosing for targeted activity in immune organs.[7]
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Burlington, Massachusetts
United States
United States
Drug Pipeline
LFD-200
Pre-clinicalKey Partnerships
Lifordi Immunotherapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Sep 27, 2024 | $70.0M | Completed | Preclinical |
To view Lifordi Immunotherapeutics's complete valuation and funding history, request access »